These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23522835)

  • 21. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
    Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
    Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
    Ferraris DV
    J Med Chem; 2010 Jun; 53(12):4561-84. PubMed ID: 20364863
    [No Abstract]   [Full Text] [Related]  

  • 26. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.
    Iwashita A; Hattori K; Yamamoto H; Ishida J; Kido Y; Kamijo K; Murano K; Miyake H; Kinoshita T; Warizaya M; Ohkubo M; Matsuoka N; Mutoh S
    FEBS Lett; 2005 Feb; 579(6):1389-93. PubMed ID: 15733846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trapping Poly(ADP-Ribose) Polymerase.
    Shen Y; Aoyagi-Scharber M; Wang B
    J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.
    Palanichamy K; Sreejayan N; Ontko AC
    J Inorg Biochem; 2012 Jan; 106(1):32-42. PubMed ID: 22112837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Design, synthesis and biological evaluation of novel para-substituted 1-benzyl-quinazoline-2, 4 (1H, 3H)-diones as human PARP-1 inhibitors].
    Yao HP; Zhu ZX; Ji M; Chen XG; Xu BL
    Yao Xue Xue Bao; 2014 Apr; 49(4):497-503. PubMed ID: 24974467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Moree WJ; Goldman P; Demaggio AJ; Christenson E; Herendeen D; Eksterowicz J; Kesicki EA; McElligott DL; Beaton G
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5126-9. PubMed ID: 18713665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
    Wang J; Wang X; Li H; Ji D; Li Y; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4127-32. PubMed ID: 27353531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
    Chevanne M; Zampieri M; Caldini R; Rizzo A; Ciccarone F; Catizone A; D'Angelo C; Guastafierro T; Biroccio A; Reale A; Zupi G; Caiafa P
    J Cell Physiol; 2010 Feb; 222(2):401-10. PubMed ID: 19890834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3.
    Lindgren AE; Karlberg T; Thorsell AG; Hesse M; Spjut S; Ekblad T; Andersson CD; Pinto AF; Weigelt J; Hottiger MO; Linusson A; Elofsson M; Schüler H
    ACS Chem Biol; 2013 Aug; 8(8):1698-703. PubMed ID: 23742272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
    Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
    Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
    Pogrebniak A; Schemainda I; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2003 Oct; 8(10):438-50. PubMed ID: 14594650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
    Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
    Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.